Jin10 data reported on September 7th that Zoli Pharmaceutical stated during an institutional survey that the research and development of Lingyi Bio's Parkinson's pipeline LY-N001 is continuing to advance, with the main preclinical research work already completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with future goals of filing IND applications in China and the US and conducting clinical research as well as global market layout. Lingyi Bio is a company focused on the R&D of innovative drugs for single-gene genetic diseases, positioned to develop gene therapies with differentiated advantages. The company increased its investment in Lingyi Bio by 20 million yuan in April 2025.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
